EUVIMEDEUVIMED entdecken
EvaluationsstudieOpen Access · CC BY 4.0

Standard E TB-Feron ELISA and Standard F TB-Feron FIA positivity rates and agreement with QuantiFERON-TB Gold Plus among TB high-risk population in Bandung, Indonesia

Dewi Kartika Turbawaty iD, Syifa Nur Maulida iD, Darin Rizka Anadhea, Mulyanusa Amarullah Ritonga, Basti Andriyoko, Rudi Wisaksana, Agnes Rengga Indrati, Nanny Natalia Mulyani Soetedjo, Laniyati Hamijoyo, Raspati Cundarani Koesoemadinata, Bachti Alisjahbana, Ida Parwati

Journal of Clinical Microbiology · 09.04.2025 · 63 (4)

DOI: 10.1128/jcm.01486-24 ↗

Kurz gefasst

Evaluationsstudie in der Zeitschrift Journal of Clinical Microbiology, erschienen am 09.04.2025. Verfasst von Dewi Kartika Turbawaty und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Pathology, Faculty of Medicine, Universitas Padjadjaran, Bandung, West Java, Indonesia. Hauptthemen laut MEDLINE: Interferon-gamma Release Tests, Tuberculosis. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 43 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Tuberculosis (TB) remains a global public health problem. The determination of tuberculosis infection (TBI) using interferon-gamma release assay has now been used widely. We aim to evaluate the positivity rates of Standard E TB-Feron enzyme-linked immunosorbent assay (TB-Feron ELISA) and Standard F TB-Feron fluorescent immunoassay (TB-Feron FIA) and their agreement with QuantiFERON-TB Gold Plus (QFT-Plus) among TB high-risk populations in Bandung City, Indonesia. We conducted a cross-sectional study, including people with a high risk of acquiring TB. We screened subjects for TB symptoms and offered chest X-ray (CXR). Anyone with cough or CXR suggestive of TB was asked to give sputum samples for GeneXpert MTB/RIF Ultra test. The positivity rates and corresponding 95% confidence intervals (CI) were calculated among patients with bacteriologically confirmed TB and among patients with no evidence of TB, no history of TB, and no known contact with TB patient (low risk of TBI). The agreement with QFT-Plus was calculated using Cohen’s κ score. We enrolled 527 subjects, and the proportion of positive results among bacteriologically confirmed TB patients were 8 (53.3%; 95% CI 26.6–78.7), 9 (60.0%, 95% CI 32.3–83.7), and 10 (66.7%, 95% CI 38.4–88.8) by TB-Feron FIA, TB-Feron ELISA and QFT-Plus. The agreement between TB-Feron FIA and QFT-Plus among all subjects was similar to that of TB-Feron ELISA and QFT-Plus (84.1%, κ = 0.66, 95% CI 0.59–0.72). TB-Feron FIA and TB-Feron ELISA showed an acceptable clinical performance compared with QFT-Plus. These tests are useful alternatives for detecting TB infection. IMPORTANCE This study evaluates the performance of two alternative interferon-gamma release assays, Standard E TB-Feron enzyme-linked immunosorbent assay and Standard F TB-Feron fluorescent immunoassay, for diagnosing tuberculosis infection (TBI) among high-risk populations in Bandung, Indonesia. Both assays demonstrated comparable clinical performance to the widely used QuantiFERON-TB Gold Plus (QFT-Plus). Given the global burden of tuberculosis, particularly in resource-limited settings, these findings suggest that the TB-Feron assays could serve as reliable alternatives to QFT-Plus for TBI detection. This research highlights the potential for these assays to improve tuberculosis diagnosis, offering a more accessible and efficient screening tool, especially for high-risk populations, and supporting broader tuberculosis surveillance.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Interferon-gamma Release TestsTuberculosisHumansIndonesiaMaleEnzyme-Linked Immunosorbent AssayAdultFemaleCross-Sectional StudiesMiddle AgedYoung AdultAdolescentSensitivity and SpecificityAgedSputumMycobacterium tuberculosis

Stichwörter der Autor:innen

Mycobacterium tuberculosisTB infectiondiagnostic performanceimmunology

Autor:innen und Institutionen

  • Department of Clinical Pathology, Faculty of Medicine, Universitas Padjadjaran, Bandung, West Java, Indonesia.
  • Hasan Sadikin General Hospital, Bandung, West Java, Indonesia.
  • Research Center for Care and Control of Infectious Disease, Universitas Padjadjaran, Bandung, West Java, Indonesia.
  • Department of Obstetrics and Gynecology, Faculty of Medicine, Universitas Padjadjaran, Bandung, West Java, Indonesia.
  • Department of Internal Medicine, Faculty of Medicine, Universitas Padjadjaran, Bandung, West Java, Indonesia.

ORCID-Profile: Dewi Kartika Turbawaty, Syifa Nur Maulida

Zitieren

APA

Turbawaty, D. K., Maulida, S. N., Anadhea, D. R., Ritonga, M. A., Andriyoko, B., Wisaksana, R., Indrati, A. R., Mulyani Soetedjo, N. N., Hamijoyo, L., Koesoemadinata, R. C., Alisjahbana, B., & Parwati, I. (2025). Standard E TB-Feron ELISA and Standard F TB-Feron FIA positivity rates and agreement with QuantiFERON-TB Gold Plus among TB high-risk population in Bandung, Indonesia. Journal of Clinical Microbiology, 63(4). https://doi.org/10.1128/jcm.01486-24

Vancouver

Turbawaty DK, Maulida SN, Anadhea DR, Ritonga MA, Andriyoko B, Wisaksana R, et al. Standard E TB-Feron ELISA and Standard F TB-Feron FIA positivity rates and agreement with QuantiFERON-TB Gold Plus among TB high-risk population in Bandung, Indonesia. Journal of Clinical Microbiology. 2025;63(4). doi:10.1128/jcm.01486-24

BibTeX
@article{Turbawaty2025,
  author = {Turbawaty, Dewi Kartika and Maulida, Syifa Nur and Anadhea, Darin Rizka and Ritonga, Mulyanusa Amarullah and Andriyoko, Basti and Wisaksana, Rudi and Indrati, Agnes Rengga and Mulyani Soetedjo, Nanny Natalia and Hamijoyo, Laniyati and Koesoemadinata, Raspati Cundarani and Alisjahbana, Bachti and Parwati, Ida},
  title = {Standard E TB-Feron ELISA and Standard F TB-Feron FIA positivity rates and agreement with QuantiFERON-TB Gold Plus among TB high-risk population in Bandung, Indonesia},
  journal = {Journal of Clinical Microbiology},
  year = {2025},
  volume = {63},
  number = {4},
  doi = {10.1128/jcm.01486-24}
}
Kostenlos starten →